Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel Free CRTX Stock Alerts

CRISM Therapeutics (CRTX) Competitors

GBX 11.40 +0.15 (+1.33%)
As of 09/3/2026 11:25 AM Eastern
Compare

CRTX vs. EMH, GDP, BZT, ZIOC, and KAV

Should you buy CRISM Therapeutics stock or one of its competitors? CRISM Therapeutics's main competitors and comparable companies include European Metals (EMH), Goldplat (GDP), Bezant Resources (BZT), Zanaga Iron Ore (ZIOC), and Kavango Resources (KAV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "metals & mining" industry.

How does CRISM Therapeutics compare to European Metals?

CRISM Therapeutics (LON:CRTX) and European Metals (LON:EMH) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

CRISM Therapeutics has a net margin of 0.00% compared to European Metals' net margin of -287.87%. European Metals' return on equity of -25.49% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
European Metals -287.87%-25.49%-2.47%

CRISM Therapeutics has a beta of 0.565, meaning that its share price is 44% less volatile than the broader market. Comparatively, European Metals has a beta of 0.291, meaning that its share price is 71% less volatile than the broader market.

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.9% of European Metals shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by insiders. Comparatively, 1.2% of European Metals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CRISM Therapeutics has higher revenue and earnings than European Metals. European Metals is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
European MetalsN/AN/A-£2.30M-£3.81N/A

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled European Metals'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
European Metals Neutral

Summary

CRISM Therapeutics beats European Metals on 6 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Goldplat?

CRISM Therapeutics (LON:CRTX) and Goldplat (LON:GDP) are both small-cap materials companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

0.3% of CRISM Therapeutics shares are owned by institutional investors. Comparatively, 1.8% of Goldplat shares are owned by institutional investors. 50.5% of CRISM Therapeutics shares are owned by company insiders. Comparatively, 39.9% of Goldplat shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Goldplat has a net margin of 3.99% compared to CRISM Therapeutics' net margin of 0.00%. Goldplat's return on equity of 11.74% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Goldplat 3.99%11.74%5.78%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Goldplat'saverage media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Goldplat Neutral

CRISM Therapeutics has a beta of 0.565, meaning that its share price is 44% less volatile than the broader market. Comparatively, Goldplat has a beta of 0.091, meaning that its share price is 91% less volatile than the broader market.

Goldplat has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Goldplat, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
Goldplat£72.22M0.43N/A£1.6810.86

Summary

Goldplat beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Bezant Resources?

CRISM Therapeutics (LON:CRTX) and Bezant Resources (LON:BZT) are both small-cap materials companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

CRISM Therapeutics has a beta of 0.565, indicating that its share price is 44% less volatile than the broader market. Comparatively, Bezant Resources has a beta of 0.852, indicating that its share price is 15% less volatile than the broader market.

Bezant Resources' return on equity of 21.18% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Bezant Resources N/A 21.18%-41.17%

0.3% of CRISM Therapeutics shares are held by institutional investors. Comparatively, 1.5% of Bezant Resources shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by company insiders. Comparatively, 7.3% of Bezant Resources shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bezant Resources had 2 more articles in the media than CRISM Therapeutics. MarketBeat recorded 2 mentions for Bezant Resources and 0 mentions for CRISM Therapeutics. Bezant Resources' average media sentiment score of 0.43 beat CRISM Therapeutics' score of 0.00 indicating that Bezant Resources is being referred to more favorably in the news media.

Company Overall Sentiment
CRISM Therapeutics Neutral
Bezant Resources Neutral

Bezant Resources has lower revenue, but higher earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Bezant Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
Bezant ResourcesN/AN/A-£8.40K£0.0117.19

Summary

Bezant Resources beats CRISM Therapeutics on 8 of the 11 factors compared between the two stocks.

How does CRISM Therapeutics compare to Zanaga Iron Ore?

Zanaga Iron Ore (LON:ZIOC) and CRISM Therapeutics (LON:CRTX) are both small-cap materials companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Zanaga Iron Ore has a beta of 1.888, suggesting that its share price is 89% more volatile than the broader market. Comparatively, CRISM Therapeutics has a beta of 0.565, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Zanaga Iron Ore had 1 more articles in the media than CRISM Therapeutics. MarketBeat recorded 1 mentions for Zanaga Iron Ore and 0 mentions for CRISM Therapeutics. Zanaga Iron Ore's average media sentiment score of 0.00 equaled CRISM Therapeutics'average media sentiment score.

Company Overall Sentiment
Zanaga Iron Ore Neutral
CRISM Therapeutics Neutral

2.2% of Zanaga Iron Ore shares are owned by institutional investors. Comparatively, 0.3% of CRISM Therapeutics shares are owned by institutional investors. 12.9% of Zanaga Iron Ore shares are owned by insiders. Comparatively, 50.5% of CRISM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zanaga Iron Ore's return on equity of -4.06% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zanaga Iron OreN/A -4.06% -2.48%
CRISM Therapeutics N/A -139.63%-26.77%

Zanaga Iron Ore has higher earnings, but lower revenue than CRISM Therapeutics. Zanaga Iron Ore is trading at a lower price-to-earnings ratio than CRISM Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zanaga Iron OreN/AN/A-£4.62K-£0.90N/A
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A

Summary

Zanaga Iron Ore beats CRISM Therapeutics on 7 of the 10 factors compared between the two stocks.

How does CRISM Therapeutics compare to Kavango Resources?

CRISM Therapeutics (LON:CRTX) and Kavango Resources (LON:KAV) are both small-cap materials companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Kavango Resources has higher revenue and earnings than CRISM Therapeutics. CRISM Therapeutics is trading at a lower price-to-earnings ratio than Kavango Resources, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISM Therapeutics£231K39.08-£792.20K-£5.10N/A
Kavango Resources£1.72M15.85-£5.48K-£0.48N/A

0.3% of CRISM Therapeutics shares are held by institutional investors. 50.5% of CRISM Therapeutics shares are held by insiders. Comparatively, 8.7% of Kavango Resources shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CRISM Therapeutics has a net margin of 0.00% compared to Kavango Resources' net margin of -869.55%. Kavango Resources' return on equity of -68.85% beat CRISM Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISM TherapeuticsN/A -139.63% -26.77%
Kavango Resources -869.55%-68.85%-14.06%

In the previous week, CRISM Therapeutics' average media sentiment score of 0.00 equaled Kavango Resources'average media sentiment score.

Company Overall Sentiment
CRISM Therapeutics Neutral
Kavango Resources Neutral

CRISM Therapeutics has a beta of 0.565, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Kavango Resources has a beta of 0.274, suggesting that its share price is 73% less volatile than the broader market.

Summary

Kavango Resources beats CRISM Therapeutics on 6 of the 11 factors compared between the two stocks.

Get CRISM Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRTX vs. The Competition

Export
MetricCRISM TherapeuticsMetals & Mining IndustryMaterials SectorLON Exchange
Market Cap£9.03M£4.05B£5.06B£2.91B
Dividend YieldN/A5.17%4.67%6.18%
P/E Ratio-2.2425.5926.14364.48
Price / Sales39.088,893.195,289.9683,785.80
Price / CashN/A29.6827.0927.89
Price / Book0.2612.7410.636.81
Net Income-£792.20K£125.14M£156.32M£5.89B
7 Day PerformanceN/A-0.25%-0.29%-0.85%
1 Month Performance26.67%21.37%16.21%2.08%
1 Year Performance12.54%57.36%45.06%21.68%

CRISM Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRTX
CRISM Therapeutics
N/AGBX 11.40
+1.3%		N/A+12.5%£9.03M£231KN/A4
EMH
European Metals
N/AGBX 14
+3.7%		N/A+51.5%£33.26MN/AN/AN/A
GDP
Goldplat
N/AGBX 18.45
-1.6%		N/A+122.6%£31.51M£72.22M10.98458
BZT
Bezant Resources
N/AGBX 0.14
flat		N/A+212.2%£31.27MN/A15.735
ZIOC
Zanaga Iron Ore
N/AGBX 3.15
-8.3%		N/A-55.7%£31.25MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CRTX) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel